

## CLAIMS

1. A hypoallergenic immunogenic molecule derived from the Phl p 6 allergen, wherein the Phl p 6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity.
2. The immunogenic molecule according to claim 1, wherein the Phl p 6 molecule is N-terminally truncated.
- 10 3. The immunogenic molecule according to claim 1, wherein the Phl p 6 molecule is C-terminally truncated.
4. The immunogenic molecule according to any one of claims 1 to 3 which is produced by recombinant techniques.
- 15 5. The immunogenic molecule according to any one of claims 1 to 3 which is produced by peptide synthetic chemistry.

*20 Nov 6.  
E1*

A hypoallergenic immunogenic combination of molecules derived from the Phl p 6 allergen, comprising (i) a Phl p 6 molecule having an N-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, and (ii) a Phl p 6 molecule having a C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity, which two molecules together encompass the complete sequence of Phl p 6.

- 25 7. A method for the hyposensitization of a mammal suffering from IgE mediated allergy against a protein allergen, comprising the step of presenting the immune system of the mammal *in vivo* to an effective amount of an immunogenic molecule according to any one of claims 1 to 5 or of an immunogenic molecule combination according to claim 6.

*X*

8. A method for inducing antibody responses in a mammal, which method comprises administering an immunogenic molecule according to ~~any one of claims 1 to 5~~ or an immunogenic molecule combination according to claim 6. *C/Claim 1*

5 9. A method for inducing T cell responses in a mammal, which method comprises administering an immunogenic molecule according to ~~any one of claims 1 to 5~~ or an immunogenic molecule combination according to claim 6. *C/Claim 1*

10 10. A method for modulating and inducing antibody responses in a mammal, which method comprises administering an immunogenic molecule according to ~~any one of claims 1 to 5~~ or an immunogenic molecule combination according to claim 6. *Claim 1*

15 11. The use of the immunogen according to ~~any one of claims 1 to 5~~, or the immunogenic molecule combination according to claim 6, for the *in vitro* diagnosis of type I allergy in a mammalian individual. *Claim 1*

20 12. The use of an immunogen according to ~~any one of claims 1 to 5~~, or the immunogenic molecule combination according to claim 6, for the preparation of a medicament to be used in the hyposensitization of a mammalian individual suffering from a type I allergy, or for the preparation of a reagent to be used in diagnosis *in vivo* of type I allergy. *Claim 1*

25 *add*

*Def*